Diagnostic accuracy of F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology

Nuclear Medicine Communications

Volumn 28, Issue 8, 2007, Pages 589-595

  Castellucci, Paolo ^a   Perrone, Anna M ^a   Picchio, Maria ^a   Ghi, Tullio ^a   Farsad, Mohsen ^a   Nanni, Cristina ^a   Messa, Cristina ^a   Meriggiola, Maria C ^b   Pelusi, Giuseppe ^b   Al Nahhas, Adil ^b   Rubello, Domenico ^c   Fazio, Ferruccio ^c   Fanti, Stefano ^c  

^a Unit of Nuclear Medicine   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Santa Maria della Misericordia Hospital Rovigo   (Italy)

Author keywords

Computed tomography (CT); Ovarian lesion; Transvaginal ultrasonography (TVUS)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; OVARY CANCER; PHYSICAL EXAMINATION; PLEURA METASTASIS; POSITRON EMISSION TOMOGRAPHY; TISSUE SECTION; TRANSVAGINAL ECHOGRAPHY; WHOLE BODY CT;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN DISEASES; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 34447571766     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3281afa256     Document Type: Article

References (41)

1. Smith LH. Early clinical detection of ovarian cancer: a review of the evidence. Exp Rev Anticancer Ther 2006; 6:1045-1052.
2. Bragg DG, Hricak H. Imaging in gynecologic malignancies. Cancer 1993; 71:1648-1651.
3. Outwater EK, Dunton CJ. Imaging of the ovary and adnexa: clinical issues and applications of MR imaging. Radiology 1995; 194:1-18.
4. Soper JT. Radiographic imaging in gynecologic oncology. Clin Obstet Gynecol 2001; 44:485-494.
5. Editorial Team of EBM Guidelines. Gynaecologic Ultrasound Examination. EBM (Evidence-Based Medicine) Guidelines. Helsinki, Finland: Duodecim Medical Publications Ltd; 2001. pp. 7-12.
6. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994; 83:434-437.
7. Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA, et al. Transvaginal ultrasound characterization of ovarian masses: Comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997; 10:192-197.
8. Timmerman D, Valentin L, Boune TH, Collins WP, Verrelst H, Vergote I, et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 2000; 16:500-505.
9. Ozols RF. Epithelial ovarian cancer. In: William JH, Carlos AP, Robert CY, editors. Principles and Practice of Gynecologic Oncology, 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 1999. pp. 841-918.
10. Tekay A. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 1996; 75:316-319.
11. Shalev E, Eliyahu S, Peleg D, Tsabari A. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol 1994; 83:594-596.
12. Curtin JP. Management of the adnexal mass. Gynecol Oncol 1994; 55(suppl):S42-S46.
13. Pittaway DE, Takacs P, Bauguess P. Laparoscopic adnexectomy: a comparison with laparotomy. Am J Obstet Gynecol 1994; 171:385-389; discussion 389-391.
14. Murta EF, Nomelini RS. Early diagnosis and predictors of malignancy of adnexal masses. Curr Opin Obstet Gynecol 2006; 18:14-19.
15. Imaoka I, Kaji Y, Hayashi T, Hayashi M, Matsuo M, Sugimura K, et al. Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics 2006; 26:1431-1434.
16. Jain KA, Friedman DL, Pettinger TW, Alagappan R, Jeffrey Jr RL, Sommer FG, et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology 1993; 186:697-704.
17. Yamashita Y, Torashima M, Hatanaka Y, Harada M, Higashida Y, Takahashi M, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995; 194:557-565.
18. Togashi K. MRI of the ovaries: normal appearance and benign disease. Radiol Clin North Am 2003; 41:799-811.
19. Tsukamoto E, Ochi S. PET/CT today: system and its impact on cancer diagnosis. Ann Nucl Med 2006; 20:255-267.
20. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-693.
21. Nakamoto Y, Saga T, Ishimori T, Manede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001; 176:1449-1454.
22. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Fujibayashi Y, Yonekura Y, et al. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA125 levels within the normal range. Ann Nucl Med 2002; 16:491-493.
23. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nuc Med Mol Imaging (published on line Dec 2006).
24. Fenchel S, Grab D, Nuessle K, Kotzerte J, Rieber A, Kreienberg R, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002; 223:780-788.
25. Kubik-Huch RA, Dorffler W, von Schulthess GK, Marincek B, Kochhi OR, Senfert B, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10:761-767.
26. Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, et al. Incremental benefits of positron emission with [F-18] fluorodeoxyglucose over computed tomography alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004; 182:227-233.
27. 18F]FDG). Gynecol Oncol 1993; 51:197-204.
28. Grab D, Flock F, Stohr I, Nussle K, Rieber A, Feuchel S, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000; 77:454-459.
29. Rieber A, Nussle K, Stohr I, Grab D, Fenchel S, Kreienberg R, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol 2001; 177:123-129.
30. Townsend DW, Beyer T. A combined PET/CT scanner: the path to true image fusion. Br J Radiol 2002; 75:s24-s30.
31. Spirtos NM, Eisekop SM, Bioke G, Schlaerth JB, Cappellari JO. Laparoscopic staging with incompletely staged cancers of the uterus, ovary, falloppian tube and primary peritoneum: a Gynecologic Oncology Group study. Am J Obstet Gynecol 2005; 193:1645-1649.
32. Benedet JL, Jones 3rd H, Hgan HY, Pecorelli S. FIGO staging classification and clinical practice guidelines in the management of gynecologic disease. Int J Gynecol Obstet 2000; 20:209-262.
33. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhort N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357:176-182.
34. Van den Burg Y. The effect of debulking surgery after induction chemotherapy on prognosis in advanced epithelial ovarian Cancer: G.C.C.G. of the European Organization for research and treatment of cancer. N Engl J Med 1995; 332:1234-1241.
35. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hunalshansen B, et al. Neoadjuvant chemotherapy followed tumor debulking prolongs survival for patients with poor prognosis in FIGO IIIc ovarian carcinoma. Cancer 2001; 92:2585-2591.
36. Robboy SJ, Kraus FT, Kurman RF. Gross description, processing and reporting of gynecologic and obstetric specimens. In: Kurman RJ, editor: Blauustein's Pathology of the Female Genital Tract, 3rd edition. New York: Springler Verlag; 1987. pp. 925-940.
37. Talerman A. Ovarian pathology. Curr Opin Obstet Gynecol 1992; 4:608-615.
38. 18F-FDG-PET/CT: an unusual finding. Cancer Imaging 2006; 23:20-23.
39. Nanni C, Farsad M, De Iaco P, Sansovii M, Erba P, Rampin L, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31:792-797.
40. Endo K, Oriuchi N, Higuchi T. PET and PET/CT using 18F FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006; 11:286-296.
41. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. Positron emission tomography is useful for the detection of pre-treatment and recurrent cervical cancer - meta-analysis. Commentary by Rubello D, Allegri V, Sansovini M. Gynecol Oncol 2006; 8:122-123.